News

Sheets Smith Wealth Management cut its IBRX stake by 7.2% to 512,572 shares.

Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.

Retail traders are watching to see whether ImmunityBio could announce preliminary Q2 revenue, with some speculating that demand for Anktiva could drive sales above $55 million.

Traders remain focused on Anktiva’s potential label expansion for papillary bladder cancer, with an FDA decision date set for Jan. 6, 2027.

Saudi Arabia is key to the bull case after ImmunityBio launched Anktiva there for certain patients with bladder and lung cancer.

ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.

The semi-annual reconstitution of the index, based on market capitalizations as of April 30, 2026, will take effect after the U.S. market close on Friday, June 26.

IBRX is already part of the Russell 2000, Russell 2500, and Russell 3000, with its current market cap around $7.67 billion.

ImmunityBio, Inc. (NASDAQ:IBRX) was among the stocks on which Jim Cramer commented, as he emphasized that SpaceX investors are betting on Elon Musk rather than the company’s earnings. When a caller mentioned that, as per their observation, the company seems to have become a “mid-cap commercial revenue generator” from a “small-cap spec play,” Cramer remarked: […]

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 10 Best Performing Growth Stocks So Far in 2026. On June 1, ImmunityBio, Inc. (NASDAQ:IBRX) reported that it presented two research posters and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held from May 29 to June 2, 2026, in Chicago. […]

Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc. (NASDAQ:IBRX) confirmed the US Food and Drug Administration accepted for review the supplemental Biologics License Application (sBLA) for ANKTIVA Plus BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer. The supplemental BLA was accepted for […]

ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The update included the first substantial ANKTIVA data readout in non small cell lung cancer and new comparative data in non muscle invasive bladder cancer. These ASCO presentations expand the clinical picture for ANKTIVA across major solid tumor types beyond bladder cancer. For investors following...

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best mid cap stocks to buy with highest upside potential. On May 22, ImmunityBio recently presented a health economic analysis at ISPOR 2026 demonstrating that ANKTIVA combined with BCG provides superior economic value compared to TAR-200 for patients with BCG-unresponsive non-muscle-invasive bladder cancer/NMIBC. Using a cost-consequence model based […]

In May 2026, ImmunityBio reported that the FDA accepted for review its supplemental Biologics License Application for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with papillary disease, setting a PDUFA action date of January 6, 2027. The filing leans heavily on QUILT 3.032 data and an FDA-indicated focus on extrapolating results from CIS patients, which could materially broaden ANKTIVA’s approved bladder cancer population if the agency agrees. We’ll now...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best momentum stocks to buy according to analysts. ImmunityBio Inc. (NASDAQ:IBRX) announced on May 19 that the U.S. Food and Drug Administration accepted for review the supplemental Biologics License Application for ANKTIVA® in combination with Bacillus Calmette-Guerin to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary […]

ImmunityBio presented its findings for ANKTIVA plus Bacillus Calmette-Guérin at the ISPOR 2026 conference.

ImmunityBio (IBRX) has been drawing attention after its lead product candidate Anktiva received FDA approval for use with BCG in certain bladder cancer patients, prompting investors to reassess the company’s broader immunotherapy pipeline and valuation. See our latest analysis for ImmunityBio. Since the FDA approval, ImmunityBio’s share price has cooled in the very short term, with 1-day and 7-day share price returns down 3% and 4.43%. However, the year-to-date share price return of 284.16%...

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's core Anktiva drug.

ImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad

IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales growth.

ImmunityBio Inc. on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to develop, import, and commercialize the Tokyo strain of BCG for bladder cancer treatment in the U.S. ImmunityBio Secures Exclusive Rights To...

Stock Moves Higher Following Patent AnnouncementShares of ImmunityBio (NASDAQ:IBRX) gained 4. 5% in premarket trading on Monday after the company announced the issuance of five U.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively t

Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...

ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?